Study title: A Phase III Randomized Single-Blind Study to Evaluate the Safety of the 9-Valent Pneumococcal, Meningococcal Group C Saccharide-CRM197 Conjugate Combination Vaccine Compared to Licensed 7-Valent Pneumococcal Conjugate Vaccine (Prevnar®) Administered to Healthy Infants
| Type of medicine: Centrally authorised medicines | |||||
| Therapeutic area: Bacterial Infections and Mycoses | |||||
| Brands: Please see report | |||||
| MAH holders: Please see report | |||||
| Assessment: | |||||
| Active substance: Pneumococcal saccharide conjugated vaccine, absorbed | |||||
| ATC code: J07AL02 | |||||
| Document link: | |||||
| Document date: | |||||
| Study number: 6004A1 D139-P003 | |||||
| EudraCT number: | |||||
| Scope of study: CLINICAL | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | Y | - | - | |